HA
CLDX icon

HC Advisors’s Celldex Therapeutics CLDX Stock Holding History

HC Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,345
Closed -$238K – 83
2022
Q4 		$238K Sell
5,345
-6,790
-56% -$242K 0.16% 67
2022
Q3 		$341K Buy
12,135
+4,510
+59% +$138K 0.23% 57
2022
Q2 		$206K Sell
7,625
-50
-0.7% -$1.45K 0.15% 73
2022
Q1 		$261K Sell
7,675
-508
-6% -$16.2K 0.17% 70
2021
Q4 		$316K Buy
8,183
+2,694
+49% +$117K 0.19% 59
2021
Q3 		$296K Sell
5,489
-927
-14% -$43.5K 0.19% 60
2021
Q2 		$215K Buy
+6,416
New +$176K 0.13% 74
2021
Q1 		– Sell
-14,791
Closed -$259K – 92
2020
Q4 		$259K Buy
14,791
+2,210
+18% +$39.8K 0.18% 70
2020
Q3 		$187K Buy
+12,581
New +$147K 0.15% 70

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return